According to the latest research analysis,the global market for Chronic Graft-versus-host Disease (cGVHD) Treatment should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
China Chronic Graft-versus-host Disease (cGVHD) Treatment market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
The United States Chronic Graft-versus-host Disease (cGVHD) Treatment market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
In terms of type, Corticosteroids segment holds a share about % in 2022 and will reach % in 2029; while in terms of application, Hospitals Pharmacies has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.
The global key manufacturers of Chronic Graft-versus-host Disease (cGVHD) Treatment include Merck KGaA, Sanofi SA, Novartis AG, Bristol Myers Squibb, Pfizer, Roche Holding AG, Johnson & Johnson, Eli Lilly and Company and Abbott Laboratories, etc. In 2022, the global top five players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive study of the global market for Chronic Graft-versus-host Disease (cGVHD) Treatment.
Data-Driven Insights: Highlights from Our Report
(1) Global Chronic Graft-versus-host Disease (cGVHD) Treatment market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.
(2) Global Chronic Graft-versus-host Disease (cGVHD) Treatment market competitive situation, revenue and market share, from 2018 to 2022.
(3) China Chronic Graft-versus-host Disease (cGVHD) Treatment market competitive situation, revenue and market share, from 2018 to 2022.
(4) Global Chronic Graft-versus-host Disease (cGVHD) Treatment segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.
(5) Global Chronic Graft-versus-host Disease (cGVHD) Treatment segment by type and by application and regional segment by type and by application.
(6) Chronic Graft-versus-host Disease (cGVHD) Treatment industry supply chain, upstream, midstream and downstream analysis.
Breaking Down Market Segments by Region: A Deep Dive Analysis
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Understanding Market Segments by Type: A Comparative Analysis
Corticosteroids
mTOR Inhibitors
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Market Segmentation by Application: Dividing Key Markets and Identifying Opportunities
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Understanding Market Segments by Key Players: Insights and Opportunities
Merck KGaA
Sanofi SA
Novartis AG
Bristol Myers Squibb
Pfizer
Roche Holding AG
Johnson & Johnson
Eli Lilly and Company
Abbott Laboratories
Takeda Pharmaceutical Company
1 Market Overview
1.1 Product Overview and Scope of Chronic Graft-versus-host Disease (cGVHD) Treatment
1.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size and Forecast
1.3 China Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size and Forecast
1.4 China Market Percentage in Global
1.4.1 By Revenue, China Chronic Graft-versus-host Disease (cGVHD) Treatment Share in Global Market, 2018-2029
1.4.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size: China VS Global, 2018-2029
1.5 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Dynamics
1.5.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Drivers
1.5.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Restraints
1.5.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Trends
1.5.4 Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Policy
2 Global Competitive Situation by Company
2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue by Company (2018-2023)
2.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Participants, Market Position (Tier 1, Tier 2 and Tier 3)
2.3 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Concentration Ratio
2.4 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Mergers & Acquisitions, Expansion Plans
2.5 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Manufacturers Product Type
3 China Competitive Situation by Company
3.1 China Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue by Company (2018-2023)
3.2 China Chronic Graft-versus-host Disease (cGVHD) Treatment Chronic Graft-versus-host Disease (cGVHD) Treatment Participants, Market Position (Tier 1, Tier 2 and Tier 3)
3.3 China Chronic Graft-versus-host Disease (cGVHD) Treatment, Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)
4 Industry Chain Analysis
4.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Chain
4.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Upstream Analysis
4.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Midstream Analysis
4.4 Chronic Graft-versus-host Disease (cGVHD) Treatment Downstream Analysis
5 Sights by Type
5.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Classification
5.1.1 Corticosteroids
5.1.2 mTOR Inhibitors
5.1.3 Tyrosine Kinase Inhibitors
5.1.4 Monoclonal Antibodies
5.1.5 Others
5.2 By Type, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & CAGR, 2018 VS 2022 VS 2029
5.3 By Type, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue, 2018-2029
6 Sights by Application
6.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Segment by Application
6.1.1 Hospitals Pharmacies
6.1.2 Retail Pharmacies
6.1.3 Online Pharmacies
6.2 By Application, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & CAGR, 2018 VS 2022 VS 2029
6.3 By Application, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue, 2018-2029
7 Sales Sights by Region
7.1 By Region, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018 VS 2022 VS 2029
7.2 By Region, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
7.3 North America
7.3.1 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & Forecasts, 2018-2029
7.3.2 By Country, North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Market Share
7.4 Europe
7.4.1 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & Forecasts, 2018-2029
7.4.2 By Country, Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & Forecasts, 2018-2029
7.5.2 By Country/Region, Asia Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Market Share
7.6 South America
7.6.1 South America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & Forecasts, 2018-2029
7.6.2 By Country, South America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Market Share
7.7 Middle East & Africa
8 Sights by Country Level
8.1 By Country, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & CAGR,2018 VS 2022 VS 2029
8.2 By Country, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.3 U.S.
8.3.1 U.S. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.3.2 By Company, U.S. Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.3.3 By Type, U.S. Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.3.4 By Application, U.S. Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.4 Europe
8.4.1 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.4.2 By Company, Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.4.3 By Type, Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.4.4 By Application, Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.5 China
8.5.1 China Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.5.2 By Company, China Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.5.3 By Type, China Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.5.4 By Application, China Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.6 Japan
8.6.1 Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.6.2 By Company, Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.6.3 By Type, Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.6.4 By Application, Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.7 South Korea
8.7.1 South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.7.2 By Company, South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.7.3 By Type, South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.7.4 By Application, South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.8 Southeast Asia
8.8.1 Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.8.2 By Company, Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.8.3 By Type, Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.8.4 By Application, Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.9 India
8.9.1 India Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.9.2 By Company, India Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.9.3 By Type, India Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.9.4 By Application, India Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.10 Middle East & Asia
8.10.1 Middle East & Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.10.2 By Company, Middle East & Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.10.3 By Type, Middle East & Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.10.4 By Application, Middle East & Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
9 Global Manufacturers Profile
9.1 Merck KGaA
9.1.1 Merck KGaA Company Information, Head Office, Market Area and Industry Position
9.1.2 Merck KGaA Company Profile and Main Business
9.1.3 Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.1.4 Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.1.5 Merck KGaA Recent Developments
9.2 Sanofi SA
9.2.1 Sanofi SA Company Information, Head Office, Market Area and Industry Position
9.2.2 Sanofi SA Company Profile and Main Business
9.2.3 Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.2.4 Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.2.5 Sanofi SA Recent Developments
9.3 Novartis AG
9.3.1 Novartis AG Company Information, Head Office, Market Area and Industry Position
9.3.2 Novartis AG Company Profile and Main Business
9.3.3 Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.3.4 Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.3.5 Novartis AG Recent Developments
9.4 Bristol Myers Squibb
9.4.1 Bristol Myers Squibb Company Information, Head Office, Market Area and Industry Position
9.4.2 Bristol Myers Squibb Company Profile and Main Business
9.4.3 Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.4.4 Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.4.5 Bristol Myers Squibb Recent Developments
9.5 Pfizer
9.5.1 Pfizer Company Information, Head Office, Market Area and Industry Position
9.5.2 Pfizer Company Profile and Main Business
9.5.3 Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.5.4 Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.5.5 Pfizer Recent Developments
9.6 Roche Holding AG
9.6.1 Roche Holding AG Company Information, Head Office, Market Area and Industry Position
9.6.2 Roche Holding AG Company Profile and Main Business
9.6.3 Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.6.4 Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.6.5 Roche Holding AG Recent Developments
9.7 Johnson & Johnson
9.7.1 Johnson & Johnson Company Information, Head Office, Market Area and Industry Position
9.7.2 Johnson & Johnson Company Profile and Main Business
9.7.3 Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.7.4 Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.7.5 Johnson & Johnson Recent Developments
9.8 Eli Lilly and Company
9.8.1 Eli Lilly and Company Company Information, Head Office, Market Area and Industry Position
9.8.2 Eli Lilly and Company Company Profile and Main Business
9.8.3 Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.8.4 Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.8.5 Eli Lilly and Company Recent Developments
9.9 Abbott Laboratories
9.9.1 Abbott Laboratories Company Information, Head Office, Market Area and Industry Position
9.9.2 Abbott Laboratories Company Profile and Main Business
9.9.3 Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.9.4 Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.9.5 Abbott Laboratories Recent Developments
9.10 Takeda Pharmaceutical Company
9.10.1 Takeda Pharmaceutical Company Company Information, Head Office, Market Area and Industry Position
9.10.2 Takeda Pharmaceutical Company Company Profile and Main Business
9.10.3 Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.10.4 Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.10.5 Takeda Pharmaceutical Company Recent Developments
10 Conclusion
11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
Historical Data (2015-2019) |
|
|
Influencing Factors |
|
|
Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
Market Size |
|
|
Market Position of Top Company |
|
|
Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
Primary Sources | Parameters | Key Data |
Market Segments(by Application, by Type) |
|
|
Total Market |
|
|